Clinical Advances in BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Where disease-, treatment-, and patient-centric education unite.
CME Education Series
To access individual activity information and to participate, please click the participation button above.
Target Audience
This activity is intended for hematology/oncology specialists and other members of the oncology multidisciplinary team.
Description
The evolving treatment landscape of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is evolving with novel therapies that may overcome the challenges of resistance and disease progression. With that in mind, this Clinical Advances in BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Where Disease-, Treatment-, and Patient-Centric Education Unite was created to provide a broad range of educational activities on ongoing therapeutic developments and patient-centered care throughout the care continuum in a variety of program formats to appeal to your individual learning preferences.
Activity Topics
Check back monthly for additional activities coming soon!
- Optimizing Treatment Pathways in CLL and MCL: Evaluating and Applying Recent Data on BTK Inhibitors.
Providers
This activity is developed through a collaboration between The Leukemia & Lymphoma Society and Medscape Oncology.
Supporters
This activity is supported by an independent educational grant from Lilly.
For questions, concerns, or assistance for people with disabilities or grievances, please contact LLS at: profeducation@LLS.org.